Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of tulisokibart in moderate to severe active Crohn's disease
CTR20242056Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tulisokibart in Crohn's disease, sponsored by Merck & Co.. Started Nov 2024; status: active.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20242056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242056.